Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Plasticity of Lineage and Immune Evasion in Primary SCLC and Transformation from LUAD to SCLC: Loss of Antigen Presentation and Shifts in Therapeutic Strategies

  • By

  • Hongying Xu

  • Benhua Li

  • Jun Yang

  • Xin Tang

  • September 4, 2026

Share

Plasticity of Lineage and Immune Evasion in Primary SCLC

Background

SCLC is known for its aggressive nature and poor long-term survival despite initial treatment responsiveness. Understanding the mechanisms of immune resistance, particularly through lineage plasticity, is crucial.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • Lineage plasticity may contribute to immune resistance in SCLC.
  • Impaired MHC-I antigen processing and presentation leads to 'immune invisibility' of tumor cells.
  • Transformation from EGFR-mutant LUAD to SCLC is a recognized mechanism of resistance.
  • Current immunotherapy strategies have shown limited durable benefits in SCLC.
  • Chemoimmunotherapy is established in defined SCLC settings.

Clinical Implications

Clinicians should consider the impact of lineage state on immune recognition and treatment response in SCLC. Understanding the mechanisms of immune evasion can inform the development of more effective therapeutic strategies.

Conclusion

The interplay between lineage plasticity and immune evasion in SCLC necessitates further research to optimize treatment approaches and improve patient outcomes.

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies
  2. The ASCO Post -- Combination Immunotherapy and Inhibitors of DNA Damage Repair in the Treatment of Small Cell Lung Cancer
  3. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline
  4. Frontiers in Immunology — Remodeling of Myeloid-Associated B-Cell Identity in Resistance to CAR T-Cell Therapy: A Framework for Hypothesis Development in Diffuse Large B-Cell Lymphoma
  5. Frontiers in Oncology — Unmasking biomarkers in small cell lung cancer: implication for precision oncology
  6. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
  7. Mechanisms of immunotherapy resistance in small cell lung cancer
  8. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Original Source(s)

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection

  • by Hongying Xu, Benhua Li, Jun Yang, Xin Tang

  • September 4, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Therapy-induced immunoediting and the evolution of cancer immune escape

Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer